Eirwen M. Miller, MD, highlights data that have impacted the treatment armamentarium for patients with endometrial cancer and mismatch repair–deficient or mismatch repair–proficient disease throughout the course of 2023.
Although there are no FDA-approved treatments specifically indicated for low-grade serous ovarian cancer, therapeutic options for these patients are rapidly expanding, with promising new approaches progressing through clinical development.
Kathleen N. Moore, MD, MS, expands on the importance of continuing to investigate PARP inhibitors in ovarian cancer and highlights key updates to have come out of the 2023 ESMO Congress